 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 February 1996 | Volume 124 Issue 3 | Pages 329-334
Given the dramatic increase in the incidence of vancomycin resistance among the enterococci and experimental evidence for the transfer of vancomycin resistance from enterococci to Staphylococcus aureus, there is concern that strains of S. aureus will emerge that are resistant to vancomycin. The result would be a highly virulent pathogen for which effective antimicrobial therapy would not be available. To prevent the nosocomial transmission of such an organism, stringent infection control policies need to be developed and implemented. We offer proposals that are based on the limited data available on the transmission and control of S. aureus and that may be used as starting points for the development of formal guidelines for the isolation of colonized and infected patients and for microbiology laboratory precautions.
Author and Article Information
From Medical College of Virginia and Virginia Commonwealth University, Richmond, Virginia; and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
PERSPECTIVE
Vancomycin-Resistant Staphylococcus aureus: Perspectives on Measures Needed for Control
Requests for Reprints: Michael B. Edmond, MD, MPH, Medical College of Virginia, PO Box 980019, Richmond, VA 23298-0019.
Current Author Addresses: Dr. Edmond: Medical College of Virginia, Division of Quality Health Care, PO Box 980019, Richmond, VA 23298-0019.
This article has been cited by other articles:
|
|
 |
|
  T. Revazishvili, L. Bakanidze, T. Gomelauri, E. Zhgenti, G. Chanturia, M. Kekelidze, C. Rajanna, A. Kreger, and A. Sulakvelidze Genetic Background and Antibiotic Resistance of Staphylococcus aureus Strains Isolated in the Republic of Georgia. J. Clin. Microbiol., October 1, 2006; 44(10): 3477 - 3483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-C. Mercier, C. Stumpo, and M. J. Rybak Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium J. Antimicrob. Chemother., July 1, 2002; 50(1): 19 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Eggimann and D. Pittet Infection Control in the ICU Chest, December 1, 2001; 120(6): 2059 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Osmon Antimicrobial Resistance: Guidelines for the Practicing Orthopaedic Surgeon J. Bone Joint Surg. Am., December 1, 2001; 83(12): 1891 - 1901. [Full Text] [PDF]
|
|
|
|
|
|
P. Vaudaux, P. Francois, B. Berger-Bachi, and D. P. Lew In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus J. Antimicrob. Chemother., February 1, 2001; 47(2): 163 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Candiani, M. Abbondi, M. Borgonovi, G. Romano, and F. Parenti In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic J. Antimicrob. Chemother., August 1, 1999; 44(2): 179 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Smith, M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, et al. Emergence of Vancomycin Resistance in Staphylococcus aureus N. Engl. J. Med., February 18, 1999; 340(7): 493 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Waldvogel New Resistance in Staphylococcus aureus N. Engl. J. Med., February 18, 1999; 340(7): 556 - 557. [Full Text]
|
|
|
|
 |
|
 J. Turnidge What can be done about resistance to antibiotics? BMJ, September 5, 1998; 317(7159): 645 - 647. [Full Text]
|
|
|
|
|
|
F. D. Lowy Staphylococcus aureus Infections N. Engl. J. Med., August 20, 1998; 339(8): 520 - 532. [Full Text] [PDF]
|
|
Article
